Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?
Explore this paper's citation graph
Summary
Interestingly, CD138+ cells from these 4 MM patients lack PTH receptor 1 and PTH-related peptide expressions, indicating that PTH could have a paracrine rather than a direct pro-tumoral effect, suggesting that the concomitant diagnosis of MM and PHTP may not be so rare.
- Type
- article
- Published
- 2020-09-09
- Cited by
- 3
- References
- 38
- OpenAlex
- https://openalex.org/W3083837988
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:221620949
Keywords
Concomitant, Primary hyperparathyroidism, Medicine, Parathyroid hormone, Multiple myeloma
References
- A Case of Multiple Myeloma Coexisting with Primary Hyperparathyroidism and Review of the Literature
- Catabolic and anabolic actions of parathyroid hormone on the skeleton
- Clinical practice. Primary hyperparathyroidism.
- PTHrP Produced by Myeloma Plasma Cells Regulates Their Survival and Pro‐Osteoclast Activity For Bone Disease Progression
- Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.
- Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities
- Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation
- Zoledronic acid may be a treatment option for hyperparathyroidism.
- Tumor-host cell interactions in the bone disease of myeloma
- Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study.
- Primary hyperparathyroidism and multiple myeloma complicated by Fanconi syndrome: a fortuitous association?
- Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system.
- Parathyroid Hormone Mediates Hematopoietic Cell Expansion through Interleukin-6
- The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
- A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.
- Serum Parathyroid Hormone Is a New Potential Risk Factor in Multiple Myeloma
- Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
- Primary hyperparathyroidism in paraneoplastic hypercalcaemia.
- Hyperparathyroidism and subsequent cancer risk in Denmark
Cited by
Related papers
- Response to: Hypercalcemia with a parathyroid hormone level of ≤50 pg/mL: Is this primary hyperparathyroidism?
- Laboratory tests in the diagnosis of hyperparathyroidism in hypercalcemic patients.
- Pancreatitis associated with primary hyperparathyroidism.
- Pathogenesis and treatment of multiple myeloma bone disease
- A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease
- Pathogenesis and treatment of multiple myeloma bone disease
- Novel therapeutic targets in myeloma bone disease
- Zoledronic acid in myeloma: MRC Myeloma IX
- Bone disease in multiple myeloma.